Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LRMR
LRMR | US
6.48
USD-0.17
-2.56%
LRMR | US
About LRMR
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
07/10/2024
Close
6.48
Open
6.71
High
6.76
Low
6.31
Larimar Therapeutics Inc. a clinical-stage biotechnology company focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601 which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia a rare progressive and fatal genetic disease. The company is headquartered in Bala Cynwyd Pennsylvania.
View LessLRMR | US
Risk
62.6
Sharpe
0.81
Luna's Score
54/100
Recommendation
Hold
Luna says (LRMR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
62.1%1 month
62.6%3 months
78.7%6 months
82.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.01
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-4.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-65.51M
MarketCap
413.47M
MarketCap(USD)
413.47M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-37.48
Short ratio
8.41
Short perc.
7.98
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.04
Range1M
2.14
Range3M
5.13
Volumes: Market Activity
Rel. volume
0.44
Price X volume
2.24M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.13 | 0.58 | Cheaper |
| Ent. to Revenue | - | 3,705.96 | - |
| PE Ratio | - | 38.75 | - |
| Price to Book | 2.01 | 16.51 | Cheaper |
| Dividend Yield | - | 2.24 | - |
| Std. Deviation (3M) | 78.68 | 75.20 | Par |
| Debt to Equity | 0.03 | -1.83 | Expensive |
| Debt to Assets | 0.02 | 0.24 | Cheaper |
| Market Cap | 413.47M | 3.67B | Emerging |
